ARGX-119 IV clinical trials

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

This study is looking at a new medicine called ARGX-119 for children aged 5 to 17 with Spinal Muscular Atrophy (SMA). It aims to find the right dose, check how safe it is, and see how well it works alongside their current SMA treatments to help muscle strength.